Welcome Arrowhead 2024 Interns! We're thrilled to introduce the bright new faces joining us this summer at Arrowhead in our Verona, Pasadena, Madison, and Scripps Ranch locations! Please join us in extending a warm welcome to our talented interns who bring fresh perspectives and enthusiasm to our teams. This summer, they'll be diving into innovative projects and gaining invaluable experience across various departments. Pasadena: Kira Rosen, Ariel Goldberg, Joshua Malilay, Joel Goodman, Diya Patel, Holly Kisiel, Kristin Yap, Noah Lyon-Hartley Madison: John Stutenbeck, Tra Yen Vy Phan, Alex Kutsunis, Marina Slawinski, Mattice Ureel, Lauren Christian Verona: Lorisa Shatrawka, Claire Riedl, Claire Jarugumilli, Matthew Schickling, Rachel Trochlell, Bianca Navari, Nick Myszkowski, Anthony Arnholt, Scripps Ranch: Julia Shoda, Saisidharth Senthilnathan, Esther Nguyen, Andrew Behne, Carina Rocha, Sanjeev Mathavaraj, Benjamin Pham, Veronica Schluep To our new interns: Get ready to make a difference, learn from some of the best in the industry, and grow both personally and professionally. Your journey with Arrowhead is just beginning, and we can't wait to see what you achieve! Let's make this summer an unforgettable experience together. #ArrowheadInterns #SummerInternship #WelcomeToArrowhead #CareerDevelopment #Innovation
Arrowhead Pharmaceuticals
Pharmaceutical Manufacturing
Pasadena, California 40,007 followers
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
About us
Arrowhead Pharmaceuticals is a clinical stage, Nasdaq listed (ticker ARWR) company developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, our therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Our RNAi-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. Our Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. The TRiM platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing and reduced costs; multiple routes of administration; and potential for improved safety. Our employees are nimble, science-driven, and innovative professionals. A career at Arrowhead offers the opportunity to collaborate with top notch scientists to rapidly discover and develop RNAi-based therapeutics to add to our growing pipeline. Arrowhead’s corporate headquarters is located in Pasadena, CA. Just north of Los Angeles and resting in the foothills of the San Gabriel Mountains. Research and development activities are in Madison, WI and San Diego, CA with a newly built GMP manufacturing facility in Verona, WI. We have invested heavily in our research workspaces to make sure our top-notch scientists can continue to quickly change the world in meaningful ways. All applicants: Please be aware of employment scams using Arrowhead’s name and the names of Arrowhead’s employees. All job related Arrowhead communication should come from the domain @arrowheadpharma.com.
- Website
-
http://www.arrowheadpharma.com
External link for Arrowhead Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 501-1,000 employees
- Headquarters
- Pasadena, California
- Type
- Public Company
- Founded
- 2004
- Specialties
- Biotech, RNA interference, hepatitis B, alpha one anti-trypsin deficiency, Drug Development, Pharmaceuticals, and Drug delivery
Locations
-
Primary
Get directions
177 E Colorado Blvd
Suite 700
Pasadena, California 91105, US
-
Get directions
502 S Rosa Rd
Madison, Wisconsin 53719, US
-
Get directions
10102 Hoyt Park Drive
San Diego, CA 92131, US
Employees at Arrowhead Pharmaceuticals
Updates
-
Today, we announced plans to advance our investigational #RNAi candidate into a Phase 3 trial for patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease based on promising Phase 2 results. Join our cardiometabolic webinar at 2:00 p.m. ET today to learn more. Details are in the full press release here: https://lnkd.in/e9ceBPTx
-
-
📅 Reminder! The second session of our summer webinar series, focused on our cardiometabolic candidates plozasiran and zodasiran, is happening today at 2:00 PM ET! Tune into the conversation to learn more about our cardiometabolic pipeline and updates: https://bit.ly/3KXJflO
-
-
Today, we announced new preclinical data on our investigational #RNAi medicine for the treatment of obesity and metabolic diseases presented at the 2024 American Diabetes Association #ADASciSessions. Learn more about the progress of our pipeline here: https://lnkd.in/eY5ifkGe
-
-
We have had a busy yet exciting couple of weeks! Arrowhead attended #EASCongress2024, #NLASessions, and #ENDO2024. At EAS and NLA, we presented the latest advancements on our cardiometabolic pipeline of #RNAi molecules including #ClinicalTrial results published in JAMA Cardiology and NEJM Group. We’re looking forward to more progress ahead as we continue to support patients. Learn more: https://lnkd.in/g3E4sYH
-
Our supply chain team recently volunteered at the Madison Ronald McDonald House Charities, preparing and serving a meal with care. At Arrowhead Pharmaceuticals, we understand the importance of giving back to our community, especially to organizations like Ronald McDonald House, which provide crucial support to families during challenging times. The local house embodies a nurturing environment where families can focus solely on their child's well-being, offering comfortable accommodations, recreational spaces like a toy room and outdoor playground, and nourishing homemade meals throughout the day. We're proud to have our Arrowheads contribute to such a meaningful cause. Check out the Madison Ronald McDonald House: https://lnkd.in/eD_3bQ2m #ArrowheadPharma #CommunityService #SupplyChain #GiveBack #Madison
-
-
-
-
-
+2
-
-
Our pivotal Phase 3 study in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome successfully met its primary and secondary endpoints showing reductions in triglycerides up to 80% and median reductions in APOC3 up to 94% at month 10. Learn more about our first #RNAi based therapy to show clinical efficacy in a Phase 3 study here: https://lnkd.in/e5aScGqE
-
We’re looking forward to presenting exciting progress across our pipeline of investigational #RNAi medicines at multiple financial and medical conferences this month. Check out the details here: https://lnkd.in/gCMER4Fe
-
-
Arrowhead Pharmaceuticals reposted this
Check out our interview with Robert Rosenson, MD, FACC, FACP, FAHA, FESC, of Mount Sinai Health System, on the unmet need in mixed hyperlipidemia and the potential of plozasiran and zodasiran, a pair of RNAi therapies from Arrowhead Pharmaceuticals. https://lnkd.in/eGsfSfbC #EAS2024 #Dyslipidemia
-
Today we announced new data from our Phase 2b double blind, randomized study on our investigational #RNAi candidate for mixed hyperlipidemia being presented by Robert Rosenson, MD, FACC, FACP, FAHA, FESC at #EASCongress2024 and simultaneously published in NEJM Group. Learn more here: https://lnkd.in/eaHjyuC4
-